Octreotide in combination with AT-101 induces cytotoxicity and apoptosis through up-regulation of somatostatin receptors 2 and 5 in DU-145 prostate cancer cells
dc.contributor.author | Degirmenci, M | |
dc.contributor.author | Erdogan, AP | |
dc.contributor.author | Bulut, G | |
dc.contributor.author | Atmaca, H | |
dc.contributor.author | Uzunoglu, S | |
dc.contributor.author | Karaca, B | |
dc.contributor.author | Karabulut, B | |
dc.contributor.author | Uslu, R | |
dc.date.accessioned | 2025-04-10T10:35:44Z | |
dc.date.available | 2025-04-10T10:35:44Z | |
dc.description.abstract | Prostate cancer (PCa) is the most common type of cancer among males. Although survival rate of early-stage PCa is high, treatment options are very limited for recurrent disease. In this study, the possible synergistic cytotoxic and apoptotic effect of octreotide in combination with AT-101 was investigated in DU-145 hormone and drug refractory prostate cancer cell line. To enlighten the action mechanisms of the combination treatment, expression levels of somatostatin receptors 2 and 5 (SSTR2 and SSTR5) were also investigated. Cell viability was measured by XTT assay. Apoptosis was assessed through DNA fragmentation analysis and caspase 3/7 assay. mRNA and protein levels of SSTR2 and SSTR5 were evaluated by qRT-PCR and western blot analysis, respectively. Octreotide in combination with AT-101 inhibited cell viability and induced apoptosis synergistically in DU-145 cells as compared to any agent alone. Combination treatment increased both SSTR2 and SSTR5 mRNA and protein levels in DU-145 cells. The data suggest that this combination therapy may be a good candidate for patients with advanced metastatic PCa do not respond to androgen deprivation. | |
dc.identifier.e-issn | 1423-0380 | |
dc.identifier.issn | 1010-4283 | |
dc.identifier.uri | http://hdl.handle.net/20.500.14701/41716 | |
dc.language.iso | English | |
dc.title | Octreotide in combination with AT-101 induces cytotoxicity and apoptosis through up-regulation of somatostatin receptors 2 and 5 in DU-145 prostate cancer cells | |
dc.type | Article |